Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.
作者信息
Ryan Julie L, Krishnan Sunil, Movsas Benjamin, Coleman C Norman, Vikram Bhadrasain, Yoo Stephen S
机构信息
Departments of Dermatology & Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA.
出版信息
Radiat Res. 2011 Nov;176(5):688-91. doi: 10.1667/rr2704.1. Epub 2011 Sep 1.
Abstract
摘要
相似文献
1
Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.
Radiat Res. 2011 Nov;176(5):688-91. doi: 10.1667/rr2704.1. Epub 2011 Sep 1.
2
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators.
Clin Cancer Res. 2011 Jan 15;17(2):222-8. doi: 10.1158/1078-0432.CCR-10-1402. Epub 2010 Nov 3.
3
Pharmacologic approaches to radiation protection.
J Clin Oncol. 2007 Sep 10;25(26):4084-9. doi: 10.1200/JCO.2007.11.5816.
4
Radioprotectors and mitigators of radiation-induced normal tissue injury.
Oncologist. 2010;15(4):360-71. doi: 10.1634/theoncologist.2009-S104.
5
Radiation protectants: current status and future prospects.
Health Phys. 2006 Mar;90(3):276; author reply 276-7. doi: 10.1097/00004032-200603000-00013.
6
Radioprotective countermeasures for radiation injury (Review).
Mol Med Rep. 2023 Mar;27(3). doi: 10.3892/mmr.2023.12953. Epub 2023 Feb 17.
7
The role of amifostine as a radioprotector.
Oncology (Williston Park). 2001 Oct;15(10):1349-54; discussion 1357-60.
8
Radiation countermeasure agents: an update.
Expert Opin Ther Pat. 2010 Jan;20(1):73-101. doi: 10.1517/13543770903490429.
9
Animal models for radiation injury, protection and therapy.
Radiat Res. 2005 Jul;164(1):100-9. doi: 10.1667/rr3388.
10
Point: Should the ALARA Concept and Image Gently Campaign Be Terminated?
J Am Coll Radiol. 2016 Oct;13(10):1195-1198. doi: 10.1016/j.jacr.2016.04.023. Epub 2016 Jun 15.
引用本文的文献
1
Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro.
Ann Plast Surg. 2020 Oct;85(4):424-429. doi: 10.1097/SAP.0000000000002110.
2
Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion.
Radiat Res. 2018 Jul;190(1):12-21. doi: 10.1667/RR14896.1. Epub 2018 Apr 19.
3
Mouse models for radiation-induced cancers.
Mutagenesis. 2016 Sep;31(5):491-509. doi: 10.1093/mutage/gew019. Epub 2016 May 21.
4
Vitamin E Analogs as Radiation Response Modifiers.
Evid Based Complement Alternat Med. 2015;2015:741301. doi: 10.1155/2015/741301. Epub 2015 Aug 20.
5
Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation.
Radiat Res. 2015 Sep;184(3):235-48. doi: 10.1667/RR14186.1. Epub 2015 Aug 18.
6
Radiation-induced myeloid leukemia in murine models.
Hum Genomics. 2014 Jul 25;8(1):13. doi: 10.1186/1479-7364-8-13.
7
2013 Dade W. Moeller lecture: medical countermeasures against radiological terrorism.
Health Phys. 2014 Aug;107(2):164-71. doi: 10.1097/HP.0000000000000082.
8
Mouse models for efficacy testing of agents against radiation carcinogenesis—a literature review.
Int J Environ Res Public Health. 2012 Dec 27;10(1):107-43. doi: 10.3390/ijerph10010107.
9
Normal tissue protection for improving radiotherapy: Where are the Gaps?
Transl Cancer Res. 2012 Jun;1(1):35-48.
10
Ionizing radiation: the good, the bad, and the ugly.
J Invest Dermatol. 2012 Mar;132(3 Pt 2):985-93. doi: 10.1038/jid.2011.411. Epub 2012 Jan 5.
本文引用的文献
1
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators.
Clin Cancer Res. 2011 Jan 15;17(2):222-8. doi: 10.1158/1078-0432.CCR-10-1402. Epub 2010 Nov 3.
2
NIAID/NIH radiation/nuclear medical countermeasures product research and development program.
Health Phys. 2010 Jun;98(6):903-5. doi: 10.1097/HP.0b013e3181bbc4df.
3
Radiation countermeasure agents: an update.
Expert Opin Ther Pat. 2010 Jan;20(1):73-101. doi: 10.1517/13543770903490429.
4
Medical countermeasures against nuclear threats: radionuclide decorporation agents.
Radiat Res. 2008 Oct;170(4):540-8. doi: 10.1667/rr1485.1.
5
Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.
Clin Pharmacol Ther. 2009 Feb;85(2):217-21. doi: 10.1038/clpt.2008.200. Epub 2008 Nov 12.
6
Medical countermeasures for radiation combined injury: radiation with burn, blast, trauma and/or sepsis. report of an NIAID Workshop, March 26-27, 2007.
Radiat Res. 2008 Jun;169(6):712-21. doi: 10.1667/RR1295.1.
7
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003.
Radiat Res. 2004 Dec;162(6):711-28. doi: 10.1667/rr3276.
8
Radiation dose reduction by cysteine.
J Cell Comp Physiol. 1953 Dec;42(3):327-41. doi: 10.1002/jcp.1030420302.
9
Does amifostine have a role in chemoradiation treatment?
Lancet Oncol. 2003 Jun;4(6):378-81. doi: 10.1016/s1470-2045(03)01132-x.
Zotero 插件